Gould Capital’s Quest Diagnostics DGX Stock Holding History

Gould Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.1K	Hold	189	–	–	0.02%	106
2026 Q1	$37K	Buy	189 +18	+11%	+$3.5K	0.02%	95
2025 Q4	$29.7K	Hold	171	–	–	0.02%	101
2025 Q3	$32.6K	Hold	171	–	–	0.02%	100
2025 Q2	$30.7K	Hold	171	–	–	0.02%	97
2025 Q1	$28.9K	Sell	171 -7	-4%	-$1.15K	0.02%	96
2024 Q4	$26.9K	Hold	178	–	–	0.02%	107
2024 Q3	$27.6K	Hold	178	–	–	0.02%	110
2024 Q2	$24.4K	Hold	178	–	–	0.02%	116
2024 Q1	$23.7K	Buy	178 +35	+24%	+$4.54K	0.02%	114
2023 Q4	$19.7K	Buy	143 +9	+7%	+$1.18K	0.01%	130
2023 Q3	$16.2K	Hold	134	–	–	0.01%	127
2023 Q2	$18.8K	Hold	134	–	–	0.01%	124
2023 Q1	$19K	Sell	134 -1	-0.7%	-$143	0.01%	123
2022 Q4	$21.1K	Hold	135	–	–	0.02%	112
2022 Q3	$17K	Hold	135	–	–	0.01%	116
2022 Q2	$18K	Hold	135	–	–	0.01%	114
2022 Q1	$18K	Buy	135 +3	+2%	+$418	0.01%	124
2021 Q4	$23K	Buy	+132	New	+$20.1K	0.02%	118

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Gould Capital's DGX Position: Q2 2026 in Review

Gould Capital held its Quest Diagnostics (DGX) position steady in Q2 2026 at 189 shares worth $40.1K. The position accounts for 0.02% of the portfolio, ranked #106.

Gould Capital first reported a position in DGX in Q4 2021 and has held it in 19 quarters since. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Gould Capital held 189 shares of Quest Diagnostics worth $40.1K as of Q2 2026.
Gould Capital left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up 0.02% of Gould Capital's portfolio in Q2 2026, its #106 holding.
Gould Capital first reported a position in Quest Diagnostics in Q4 2021 and has held it in 19 quarters since.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Gould Capital's 13F filing for Q2 2026, filed 7 Aug 2026.